Ecteinascidin-743 inhibits activated but not constitutive transcription
- PMID: 12067978
Ecteinascidin-743 inhibits activated but not constitutive transcription
Abstract
Ecteinascidin-743 (ET-743) is a promising chemotherapeutic agent currently in Phase III clinical trials. Previous studies indicated a novel spectrum of activity for this agent, including transcriptional inhibition. Initially hypothesized to target a single transcription factor (NF-Y), we now show that ET-743 is a more general inhibitor of activated transcription. Induction of the Sp1-regulated p21 gene by Trichostatin A (TSA) was blocked by ET-743 at concentrations that had minimal effect on uninduced (constitutive) expression. Moreover, ET-743 blocked induction of Gal4 fusion proteins by TSA without affecting activation mediated by the fusion proteins in the absence of the inducer. Finally, microarray analysis of SW620 cells treated with TSA and/or ET-743 indicated that activation of TSA-responsive promoters was blocked by ET-743 with little affect on nonresponsive promoters. These results, taken together with previous reports, leads us to suggest a mechanism whereby ET-743 is a novel, potent, and general inhibitor of activated but not uninduced transcription.
Similar articles
-
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4. doi: 10.1073/pnas.97.12.6780. Proc Natl Acad Sci U S A. 2000. PMID: 10841573 Free PMC article.
-
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6775-9. doi: 10.1073/pnas.97.12.6775. Proc Natl Acad Sci U S A. 2000. PMID: 10841572 Free PMC article.
-
Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.J Biol Chem. 2003 Oct 10;278(41):40400-7. doi: 10.1074/jbc.M301964200. Epub 2003 Jul 24. J Biol Chem. 2003. PMID: 12881530
-
ET-743: more than an innovative mechanism of action.Anticancer Drugs. 2002 May;13 Suppl 1:S3-6. Anticancer Drugs. 2002. PMID: 12173491 Review.
-
[Ecteinascidin 743].Bull Cancer. 1999 Feb;86(2):139-41. Bull Cancer. 1999. PMID: 10094523 Review. French. No abstract available.
Cited by
-
Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling.Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9613-8. doi: 10.1073/pnas.0510909103. Epub 2006 Jun 13. Proc Natl Acad Sci U S A. 2006. PMID: 16772382 Free PMC article.
-
Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.Drugs. 2010 Feb 12;70(3):355-76. doi: 10.2165/11202860-000000000-00000. Drugs. 2010. PMID: 20166769 Review.
-
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.Br J Cancer. 2003 Dec 15;89(12):2305-11. doi: 10.1038/sj.bjc.6601431. Br J Cancer. 2003. PMID: 14676811 Free PMC article.
-
Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin.Oncol Lett. 2014 Jan;7(1):47-49. doi: 10.3892/ol.2013.1646. Epub 2013 Oct 29. Oncol Lett. 2014. PMID: 24348818 Free PMC article.
-
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072764 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials